This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Pharma reform package ready for negotiations with EU Parliament

( June 4, 2025, 13:43 GMT | Official Statement) -- MLex Summary: Makers of innovative drugs will be able to prevent rivals from accessing the data used to develop them for a period of eight years, under a position on new rules for the pharma sector that EU governments agreed on today. The pharma package also expands an IP exemption for generic medicines to include submissions for procurement tenders, to back earlier market entry of generic and biosimilar medicinal products. EU member states are now ready to start talks with the European Parliament with a view to reaching an agreement on the reform.Statement follows. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections